Table of Contents
Apixaban is an oral anticoagulant used to reduce the risk of stroke in patients with atrial fibrillation (AF) and to treat venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Proper dosing is essential to maximize efficacy and minimize bleeding risks. This article provides comprehensive dosing guidelines for apixaban in these conditions.
Dosing in Atrial Fibrillation
The standard dose of apixaban for stroke prevention in non-valvular atrial fibrillation is 5 mg taken twice daily. However, a reduced dose is recommended for certain patients to decrease bleeding risk.
Standard Dose
5 mg orally twice daily is the typical dose for eligible patients without dose-reduction criteria.
Reduced Dose Criteria
- Age 80 years or older
- Body weight 60 kg or less
- Serum creatinine 1.5 mg/dL or higher
Patients meeting any two of these criteria should receive a reduced dose of 2.5 mg twice daily.
Dosing for VTE Treatment
Initial treatment of VTE with apixaban involves a higher dose for the first 7 days, followed by a maintenance dose. The dosing regimen is as follows:
Initial Phase (First 7 Days)
10 mg twice daily for the first 7 days.
Maintenance Phase
After the initial phase, reduce to 5 mg twice daily for continued treatment and prevention of recurrence.
Special Considerations
In patients with renal impairment, dose adjustments are necessary. For those with a creatinine clearance (CrCl) of 15-29 mL/min, a dose of 2.5 mg twice daily is recommended for AF. Apixaban is not recommended for patients with CrCl below 15 mL/min.
For patients with hepatic impairment, assess bleeding risk before initiating therapy. Consult current guidelines for specific recommendations.
Monitoring and Adjustments
Routine laboratory monitoring is not required for apixaban, but renal function should be checked periodically, especially in patients with existing renal disease. Adjust dosing based on renal function, age, weight, and bleeding risk.
Summary
- For AF: 5 mg twice daily; reduce to 2.5 mg twice daily if criteria met.
- For VTE: 10 mg twice daily for 7 days, then 5 mg twice daily.
- Adjust doses in renal impairment; avoid in severe hepatic impairment.
- Monitor renal function periodically.
Following these dosing guidelines helps optimize treatment outcomes and minimizes adverse effects. Always consider individual patient factors when prescribing apixaban.